Science News About Treatments

NIMH awarded six research grants for studies to develop a learning health care system for the treatment of early psychosis.

FDA approval of the postpartum depression treatment brexanolone represents the final phase of a bench-to-bedside journey for this drug — a journey that began in the NIMH Intramural Research Program. NIMH experts are available to provide information on postpartum depression and the importance of, and the science underlying, this new drug.

A new study looking at interactions among sleep, energy, activity level, and mood suggests that instability in activity and sleep systems could lead to mood changes. The findings suggest new targets for depression treatment.

Two recent studies add to the evidence that team-based early intervention services are feasible in real-world health care settings and result in improved outcomes for patients.

Findings from NIMH’s Recovery After an Initial Schizophrenia Episode (RAISE) project indicate that team-based coordinated specialty care (CSC) for first episode psychosis (FEP) results in more optimal prescribing of antipsychotics and fewer side effects when compared with typical community care.

Research supported by the National Institute of Mental Health has shown that a shorter therapy (written exposure therapy) may be just as effective as lengthier first-line treatments for PTSD.

A recent clinical trial of a psychotherapy called dialectical behavior therapy (DBT)—which has been shown to be effective in reducing suicide-related behavior in adults—showed that DBT can also reduce suicide attempts and suicidal behavior in adolescents.

People infected with the human immunodeficiency virus, known as HIV, display reductions in brain volume compared with people who are not infected with HIV, but now an NIMH-funded study has shed light on the course of this deterioration and shows that antiretroviral treatment started in the first few years of infection may stop these brain changes.

Scientists have deciphered the molecular structure of a widely-prescribed antipsychotic docked in its key human brain receptor. The discovery may hold clues to designing better treatments for schizophrenia, bipolar disorder and other mental illnesses.

An expert panel has published guidelines for treatment of Pediatric Acute Onset Neuropsychiatric Syndrome (PANS) and a subset of patients diagnosed with PAN Disorder Associated with Streptococcal Infection (PANDAS).

Using brain imaging to track the effects of treatment of post-traumatic stress disorder (PTSD), scientists have identified a brain circuit on which a frequently used and effective psychotherapy (prolonged exposure) acts to quell symptoms. The findings help explain why the neural circuit identified is a promising target for additional treatment development, including brain stimulation therapies.

A streamlined behavioral therapy delivered in a pediatrics practice offered much greater benefit to youth with anxiety and depression than a more standard referral to mental health care with follow-up in a clinical trial comparing the two approaches.

Beginning May 31, 2017, the National Institute of Mental Health (NIMH) will launch a speaker series intended to bring together leaders in the field conducting research using non-invasive brain stimulation and functional imaging including EEG, fMRI, and transcranial magnetic stimulation (TMS).

Long overlooked as a mere “relay,” an egg-like structure in the middle of the brain also turns out to play a pivotal role in tuning-up thinking circuity. A trio of studies in mice are revealing that the thalamus sustains the ability to distinguish categories and hold thoughts in mind. It might even become a target for interventions for psychiatric disorders marked by working memory problems, such as schizophrenia.

A study of how policies restricting pharmaceutical promotion to physicians affect medication prescribing found that physicians in academic medical centers (AMCs) prescribed fewer of the promoted drugs, and more non-promoted drugs in the same drug classes, following policy changes to restrict marketing activities at those medical centers.

Scientists have discovered the molecular structure of LSD in its human brain receptor.

Researchers have discovered molecular mechanisms that may underlie a woman’s susceptibility to disabling irritability, sadness, and anxiety in the days leading up to her menstrual period.

Medicare’s new policy supports Collaborative Care and could improve the lives of millions of people with behavioral health conditions.

Scientists have synthesized a molecule with a unique profile of highly specific pain-relieving properties and demonstrated its efficacy in mice.

An individualized program of follow-up treatment with electroconvulsive therapy (ECT) combined with an antidepressant was effective in preventing relapse in patients 60 years and older who had had a successful initial course of treatment for severe depression.

A chemical byproduct, or metabolite, created as the body breaks down likely holds the secret to its rapid antidepressant action .

On March 17, 2016, NIMH hosts a Facebook Q&A on electroconvulsive therapy with expert Dr. Sarah Lisanby.

Is mobile mental health research the next frontier for smartphones? Based on Dr. Patricia Areán’s pioneering BRIGHTEN study, research via smartphone app is already a reality.

Coordinated Specialty Care for First Episode Psychosis is Cost Effective

On October 16, the Centers for Medicare and Medicaid Services announced support for a new treatment for first episode psychosis called coordinated specialty care (CSC). This decision means more clinics may be able to offer CSC and it may become more readily available.

Researchers find antipsychotic use among older adults increases with age despite known health risks. In 2010, more than 3/4 of seniors receiving an antipsychotic prescription had no documented clinical psychiatric diagnosis during the year. In addition, among those who did have a diagnosed mental disorder and/or dementia, nearly half of the oldest patients had dementia, regardless of FDA warnings that antipsychotics increase mortality in people with dementia.

New research shows that a team-based, coordinated specialty care treatment plan produces better outcomes than typical community care for people with first episode psychosis. Investigators also found that treatment is most effective for people who receive care soon after psychotic symptoms begin.

NIMH, NIH, and the National Institute of Justice are collaborating on a 4-year, $6.8 million study called Suicide Prevention for at-Risk Individuals in Transition or “SPIRIT.” The study focuses on the high-risk individuals who are transitioning from jail to community. SPIRIT is NIMH’s first major investment in suicide prevention in the justice system.

View the archived webinars with NIMH experts and grantees, which focus on training, research, and methodology

Boys are more likely than girls to receive an antipsychotic prescription regardless of age, according to a new study published in JAMA Psychiatry.

Many patients with first-episode psychosis receive medications that do not meet guidelines. A study finds that almost 40 % of people with first-episode psychosis in community mental health clinics across the country might benefit from medication treatment changes.

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of – and ahead of – its other antidepressant effects.

A groundbreaking study will help researchers learn more about treating people with suicidal thoughts. Nearly 20,000 patients will be able to enroll in the trial. One of the treatments being tested was developed with the help of other patients

Many patients with psychosis develop health risks associated with premature death early in the course of their mental illness, researchers have found.

NIMH Twitter Chat on Depression and the Development of Novel Medications

Treatment adherence is a problem among people with schizophrenia, who may not take medications because they don’t perceive its need or benefit, don’t like the side effects, or forget. To combat this issue, long-acting injectable medications are administered every 2-4 weeks. But are the new forms of these drugs better than the old ones?